Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers.

Nature communications - 19 Mar 2024

Iyer R Sumanth, Needham Sarah R, Galdadas Ioannis, Davis Benjamin M, Roberts Selene K, Man Rico C H, Zanetti-Domingues Laura C, Clarke David T, Fruhwirth Gilbert O, Parker Peter J, Rolfe Daniel J, Gervasio Francesco L, Martin-Fernandez Marisa L

Abstract excerpt

The Epidermal Growth Factor Receptor (EGFR) is frequently found to be mutated in non-small cell lung cancer. Oncogenic EGFR has been successfully targeted by tyrosine kinase inhibitors, but acquired drug resistance eventually overcomes the efficacy of these treatments. Attempts to surmount this therapeutic challenge are hindered by a poor understanding of how and why cancer mutations specifically amplify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Ligands

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 38503739
DOI: 10.1038/s41467-024-46284-x
PMCID: PMC10951324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers.PMID 38503739Read ↗

Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistanceSemantic proximity Read ↗

EGFR forms ligand-independent oligomers that are distinct from the active state.Semantic proximity Read ↗

Steric disruption of EGFR oligomerization overcomes therapy resistance in non-small cell lung cancer.Semantic proximity Read ↗

Ligand-independent EGFR oligomers do not rely on the active state asymmetric kinase dimerSemantic proximity Read ↗

Allosteric activation of preformed EGF receptor dimers by a single ligand binding eventSemantic proximity Read ↗

Mechanistic insights into the activation of oncogenic forms of EGF receptor.Semantic proximity Read ↗

Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.Semantic proximity Read ↗

Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer.Semantic proximity Read ↗

The role of kinase domain dimerization in EGFR activation.Semantic proximity Read ↗

Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”Semantic proximity Read ↗

EGFR Oncogenes Expressed In Glioblastoma Are Activated As Covalent Dimers And Paradoxically Stimulated By ErlotinibSemantic proximity Read ↗

A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.